Science Corp’s brain‑tech startup valued at $3.5 billion after $400 m round

Science Corp’s brain‑tech startup valued at $3.5 billion after $400 m round

Lead – According to TechCrunch, Science Corporation, the medical‑technology startup founded by former Neuralink president Max Hodak, announced a $400 million Series D financing that lifts its valuation to $3.5 billion. The round, closed in November 2026, brings in investors such as Khosla Ventures and Y Combinator and is intended to expand the company’s PRIMA retinal implant into the United States while it prepares early‑stage human trials of a brain‑interface sensor.


Science Corporation was established in 2021 by Max Hodak, who, as reported by TechCrunch, entered a graduate neuroscience laboratory as an undergraduate and has pursued biotechnology ever since. Hodak’s prior role as president of Neuralink is also highlighted in the source.

The company’s most advanced product to date is PRIMA, a wearable and implantable chip designed to restore partial vision for patients with age‑related macular degeneration (AMD). According to TechCrunch, the device has received approval for use in Europe and is currently available in Germany. The same report notes that PRIMA is being evaluated for additional ocular conditions, specifically Stargardt’s disease, a form of inherited blindness.

During a presentation at TechCrunch Disrupt, Hodak announced that PRIMA is now in trial for Stargardt’s disease patients. As reported by TechCrunch, the new funding will enable Science Corporation to seek U.S. market entry through the Food and Drug Administration’s Humanitarian Device Exemption (HDE) pathway. The HDE route, according to the source, permits experimental medical technologies to be used for rare conditions; the company has convinced the FDA that advanced macular degeneration affecting both eyes meets the rarity criteria required for this exemption.

The $400 million Series D round was led by a consortium of investors that includes Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech, as stated by TechCrunch. The infusion values Science Corporation at $3.5 billion, a figure confirmed by a person familiar with the deal, according to the same source.

Beyond PRIMA, Science Corporation’s founding mission, as described by TechCrunch, is to create a direct interface with the human brain using a bio‑hybrid sensor that merges cultured neurons with silicon circuitry. The company is reportedly in the design phase for its first human trials of this brain‑interface device. Yale neurosurgery professor Murat Günel is identified in the source as a collaborator, and he indicated that the technology could eventually address Parkinson’s disease and other neurological injuries or illnesses.

The strategic focus on regulatory approval and clinical validation reflects a broader trend among neurotechnology firms to secure credible pathways to market. According to TechCrunch, Science Corporation’s pursuit of the HDE route underscores its emphasis on rare‑disease indications as a pragmatic entry point into the highly regulated U.S. medical‑device landscape.

Analysis (Opinion) – While the valuation of $3.5 billion places Science Corporation among the most highly valued neurotech startups, the company’s reliance on a limited set of early‑stage clinical data for both retinal and brain applications suggests that significant milestones remain before widespread commercial adoption. The involvement of established investors and an academic partner may mitigate some execution risk, yet the transition from European approval to U.S. regulatory clearance often encounters unforeseen challenges.

Conclusion – As reported by TechCrunch, Science Corporation’s latest financing round not only amplifies its financial standing but also accelerates the rollout of PRIMA in the United States and the development of its brain‑interface platform. The company’s next steps will likely focus on navigating the FDA’s HDE process for AMD and launching the first human trials of its hybrid sensor, milestones that will determine whether its ambitious vision of direct brain communication can move from prototype to therapeutic reality.

Source: TechCrunch

Frequently Asked Questions

What amount did Science Corporation raise in its latest funding round?

According to TechCrunch, the company raised $400 million in a Series D round.

Which investors participated in the Series D financing?

As reported by TechCrunch, the round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

What regulatory pathway is Science Corporation pursuing to bring PRIMA to the U.S. market?

According to TechCrunch, the company is seeking approval through the FDA’s Humanitarian Device Exemption, which allows experimental devices for rare conditions.

Source: TechCrunch — Read more

💻 Related Articles